SpyGlass Pharma, a late-stage biopharmaceutical company, today announced that the first patients have been randomized in two registrational Phase III clinical trials of its lead product candidate, the ...
SpyGlass Pharma has randomized the first patients in its 2 registrational phase 3 clinical trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System) for the lowering of intraocular pressure (IOP) ...
First-in-Human(FIH)Trialat36Months: PhaseI/IITrialat3Months: 37% and 36% reduction in mean IOP with 98% and 96% of patients off topical IOP-lowering drops in 78 mcg and 39 mcg dose groups, ...
All patients achieved 20/30 or better best corrected distance visual acuity (BCDVA) Significant IOP reduction at 18 months was also demonstrated with 100% of patients off all topical IOP-lowering ...
SpyGlass Pharma (SGP) has filed for a proposed Nasdaq IPO.
Jean-Frédéric Viret Jean-Frédéric Viret ALISO VIEJO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a late-stage ...
37% and 36% reduction in mean IOP with 98% and 96% of patients off topical IOP-lowering drops in 78 mcg and 39 mcg dose groups, respectively 100% of patients achieved 20/40 or better BCDVA and a mean ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results